Antihypertensive medications and their effects on lipid metabolism. 2008

Mrunalini Deshmukh, and Ho Won Lee, and Samy I McFarlane, and Adam Whaley-Connell
Department of Medicine, Box 50, State University of New York Health Science Center at Brooklyn, Kings County Hospital Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA. mrunalini.deshmukh@downstate.edu

Hypertension and hyperlipidemia are interrelated and share common pathophysiologic mechanisms, such as insulin resistance and endothelial dysfunction. Accumulating evidence shows that it is important to regulate hypertension and hyperlipidemia to reduce cardiovascular risk. However, medications such as beta-blockers and thiazide diuretics, which are widely used for blood pressure regulation, are known to have several metabolic side effects. Despite deleterious effects on glucose metabolism and lipid metabolism, these medications have been proven to reduce cardiovascular risk. On the other hand, calcium channel blockers, angiotensin-converting enzyme inhibitors, and alpha-blockers have either no effect or favorable effects on the lipid profile. This review outlines the need to control hypertension, options for several antihypertensive medications, their differing effects on lipid metabolism, and the clinical implications of their effects on lipid parameters.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D050171 Dyslipidemias Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL. Dyslipoproteinemias,Dyslipidemia,Dyslipoproteinemia
D050356 Lipid Metabolism Physiological processes in biosynthesis (anabolism) and degradation (catabolism) of LIPIDS. Metabolism, Lipid

Related Publications

Mrunalini Deshmukh, and Ho Won Lee, and Samy I McFarlane, and Adam Whaley-Connell
February 2012, Current atherosclerosis reports,
Mrunalini Deshmukh, and Ho Won Lee, and Samy I McFarlane, and Adam Whaley-Connell
January 1987, Clinical therapeutics,
Mrunalini Deshmukh, and Ho Won Lee, and Samy I McFarlane, and Adam Whaley-Connell
December 1996, Wiener klinische Wochenschrift,
Mrunalini Deshmukh, and Ho Won Lee, and Samy I McFarlane, and Adam Whaley-Connell
January 2001, Klinicheskaia meditsina,
Mrunalini Deshmukh, and Ho Won Lee, and Samy I McFarlane, and Adam Whaley-Connell
March 1984, Klinische Wochenschrift,
Mrunalini Deshmukh, and Ho Won Lee, and Samy I McFarlane, and Adam Whaley-Connell
February 1983, The American journal of cardiology,
Mrunalini Deshmukh, and Ho Won Lee, and Samy I McFarlane, and Adam Whaley-Connell
June 1991, Journal of hypertension,
Mrunalini Deshmukh, and Ho Won Lee, and Samy I McFarlane, and Adam Whaley-Connell
October 1987, The Journal of family practice,
Mrunalini Deshmukh, and Ho Won Lee, and Samy I McFarlane, and Adam Whaley-Connell
June 2016, Preventive medicine reports,
Mrunalini Deshmukh, and Ho Won Lee, and Samy I McFarlane, and Adam Whaley-Connell
January 1989, Psychopharmacology bulletin,
Copied contents to your clipboard!